Acorn Capital Advisors LLC Acquires Shares of 643,381 Bicara Therapeutics Inc. (NASDAQ:BCAX)

Acorn Capital Advisors LLC purchased a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 643,381 shares of the company's stock, valued at approximately $11,208,000. Bicara Therapeutics accounts for about 6.1% of Acorn Capital Advisors LLC's investment portfolio, making the stock its 6th biggest holding. Acorn Capital Advisors LLC owned approximately 1.18% of Bicara Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC acquired a new position in shares of Bicara Therapeutics during the third quarter valued at about $1,239,000. Legal & General Group Plc bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth approximately $33,000. JPMorgan Chase & Co. grew its holdings in shares of Bicara Therapeutics by 8,768.5% during the 4th quarter. JPMorgan Chase & Co. now owns 64,740 shares of the company's stock worth $1,128,000 after purchasing an additional 64,010 shares in the last quarter. Barclays PLC acquired a new position in shares of Bicara Therapeutics in the third quarter valued at $255,000. Finally, Bank of New York Mellon Corp bought a new position in Bicara Therapeutics in the fourth quarter worth $701,000.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. HC Wainwright cut their target price on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a report on Thursday, March 27th. Wells Fargo & Company initiated coverage on shares of Bicara Therapeutics in a report on Thursday, April 17th. They set an "underweight" rating and a $8.00 price target for the company. Wedbush reiterated an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research note on Thursday, March 27th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $13.01 price target on shares of Bicara Therapeutics in a research report on Thursday, March 13th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $32.43.

Bicara Therapeutics Price Performance

NASDAQ:BCAX traded down $0.21 during mid-day trading on Friday, reaching $14.50. 728,148 shares of the company's stock were exchanged, compared to its average volume of 480,490. Bicara Therapeutics Inc. has a one year low of $8.91 and a one year high of $28.09. The business's fifty day simple moving average is $12.94 and its two-hundred day simple moving average is $15.88.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08). As a group, sell-side analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.